)
NUPLAZID® (pimavanserin)
Please read the full Prescribing Information, including Boxed WARNING
To improve healthcare in our community/what is expanded access?
We believe completing clinical research and partnering with regulatory authorities is the best approach to improve health outcomes for people with an illness or disease. For this reason, Acadia does not have an expanded access program that offers patients access to our investigational therapies outside of clinical trials or prior to FDA approval.
We believe clinical trials are the most appropriate way for patients to access investigational medicines developed by Acadia. In these trials, the safety and efficacy of investigational medicines is rigorously assessed by Acadia and the relevant regulatory agencies in order to understand the medicine’s benefits, risks, and appropriate use, including whether or not it should be approved as a therapy for its intended use. Obtaining regulatory approval is the best way to bring safe and effective medicines to the greatest number of patients who may benefit from treatment.